<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004614.pub2" GROUP_ID="INFECTN" ID="608303030315554714" MERGED_FROM="" MODIFIED="2009-08-07 09:29:25 +0200" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="LORT" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2009-08-04 14:42:06 +0100" MODIFIED_BY="Anne-Marie Stephani">
<TITLE>Unit-dose packaged drugs for treating malaria</TITLE>
<CONTACT>
<PERSON ID="14321" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Lois</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Orton</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>Lois.Orton@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Nursing, Midwifery and Social Work</DEPARTMENT>
<ORGANISATION>University of Manchester</ORGANISATION>
<ADDRESS_1>University Place</ADDRESS_1>
<ADDRESS_2>Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 306 7888</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-08-04 14:42:06 +0100" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="14321" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Lois</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Orton</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>Lois.Orton@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Nursing, Midwifery and Social Work</DEPARTMENT>
<ORGANISATION>University of Manchester</ORGANISATION>
<ADDRESS_1>University Place</ADDRESS_1>
<ADDRESS_2>Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 306 7888</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14278" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Guy</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Barnish</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Parasitology</POSITION>
<EMAIL_1>gbarnish@liv.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Disease Control Strategy Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 708 9393</PHONE_1>
<PHONE_2>+44 151 705 3153</PHONE_2>
<FAX_1>0151 705 3369</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-05-26 19:58:46 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="25" MONTH="3" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="2" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="7" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2009-08-04 12:02:27 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-08-04 12:02:27 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>One new trial included in the review. Inclusion criteria updated to exclude controlled before and after studies. Treatment failure at day 14 removed from primary outcome measures and made secondary. No change to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-07-30 08:42:09 +0100" MODIFIED_BY="Anne-Marie Stephani">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-24 14:40:03 +0100" MODIFIED_BY="Jenny Bellorini">
<DATE DAY="3" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-30 08:42:09 +0100" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="11" MONTH="1" YEAR="2005"/>
<DESCRIPTION>
<P>Issue 2, 2005 (Deviations from protocol)<BR/>(1) Title: changed from 'Pre-packaged drugs for treating malaria' to 'Unit-dose packaged drugs for treating malaria' for a more specific definition of the intervention.<BR/>(2) Types of intervention: different drug formulations may now be used in the intervention and control arms, as these may form useful comparisons, but we will not combine the data with data from studies using the same formulation in intervention and control arms.<BR/>(3) Types of outcomes: treatment failure outcome measures altered to conform to new standards; this involved removing "parasite failure rate" and replacing "early" and "late" treatment failure with treatment failure on or by day 14/28.<BR/>(4) Methods of the review: inclusion of 80% of all randomized participants considered adequate, rather than 90%, to take into account the difficulty in carrying out studies of this type of intervention.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-04 14:45:25 +0100" MODIFIED_BY="Anne-Marie Stephani">
<SUMMARY MODIFIED="2009-07-30 08:43:12 +0100" MODIFIED_BY="Anne-Marie Stephani">
<TITLE MODIFIED="2009-07-30 08:43:12 +0100" MODIFIED_BY="Anne-Marie Stephani">Unit-dose packaging of drugs for treating malaria</TITLE>
<SUMMARY_BODY MODIFIED="2009-03-25 17:43:07 +0000" MODIFIED_BY="[Empty name]">
<P>Malaria is a parasitic disease spread by mosquitoes in areas such as sub-Saharan Africa, South-East Asia and South America. Millions of people are infected with malaria each year. It is thought that packaging a course of treatment in units of a single dose may better ensure the correct dosage is taken, thus increasing the success of treatment. The review found insufficient good quality evidence from randomized controlled trials to determine if unit-dose packaging of drugs saves lives, but there is some indication that it might improve treatment adherence. More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-04 14:45:19 +0100" MODIFIED_BY="Anne-Marie Stephani">
<ABS_BACKGROUND MODIFIED="2009-06-25 14:36:54 +0100" MODIFIED_BY="[Empty name]">
<P>Unit-dose packaging of antimalarial drugs may improve the success of malaria treatments by making it easier for patients to take them correctly.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-06-25 14:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>To summarize the effects of unit-dose packaged treatment on treatment failure and treatment adherence in people with uncomplicated malaria.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-03-25 16:11:34 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Infectious Diseases Group Specialized Register (February 2009); CENTRAL (<I>The Cochrane Library</I> Issue 1, 2009); MEDLINE (1966 to February 2009); EMBASE (1980 to February 2009); LILACS (February 2009); conference proceedings, and reference lists of articles. We also contacted pharmaceutical companies, organizations, and researchers in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-06-25 14:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs), cluster-RCTs and quasi-RCTs of unit-dose packaged drugs for treating uncomplicated malaria.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-30 09:15:50 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>We independently assessed trial eligibility and risk of bias, and extracted data for an intention-to-treat analysis, where possible. We combined binary data using risk ratio (RR) and the fixed-effect model, and presented them with 95% confidence intervals (CI). We attempted to contact trial authors for additional information.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-04 14:45:14 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>One RCT (203 participants), three quasi-RCTs (895 participants), and one cluster-RCT (six health facilities) met the inclusion criteria. Trials were generally of poor methodological quality, and none adequately assessed treatment failure. Unit-dose packaged drugs (in conjunction with prescriber training and patient information) appeared to be associated with higher participant-reported treatment adherence in all trials.</P>
<P>A meta-analysis of two trials (596 participants) showed that participant-reported treatment adherence was slightly higher with blister-packed tablets compared with tablets in paper envelopes (RR 1.18, 95% CI 1.12 to 1.25). Two trials using tablets in sectioned polythene bags as the intervention also noted an increase in participant-reported treatment adherence: the cluster-RCT (six clusters) compared it with tablets in paper envelopes, and the other trial compared it with syrup in bottles (RR 2.15, 95% CI 1.76 to 2.61; 299 participants).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-08-04 14:45:19 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>There is insufficient evidence to know if the effects of unit-dose packaged antimalarial drugs reduce treatment failure. Unit-dose packaging, supported by prescriber training and patient information, appears to improve participant-reported treatment adherence, but these data come from trials with methodological limitations.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-08-04 14:45:25 +0100" MODIFIED_BY="Anne-Marie Stephani">
<BACKGROUND MODIFIED="2009-08-04 12:26:50 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Treating malaria</HEADING>
<P>Malaria is caused by the <I>Plasmodium</I> parasite, which is spread by mosquitoes mainly in Africa, Asia, and South America. Millions of people are infected with malaria each year and many will die (<LINK REF="REF-WHO-2004" TYPE="REFERENCE">WHO 2004</LINK>). The World Health Organization (WHO) promotes rapid diagnosis and prompt treatment of malaria to reduce the burden of the disease (<LINK REF="REF-WHO-1993" TYPE="REFERENCE">WHO 1993</LINK>). There is a challenge in ensuring that people are receiving effective drugs to treat malaria. Once these drugs are available, interventions that aid people in taking the correct treatment regimen will help maximize their effectiveness. Suboptimal dosing results in low blood concentrations and inadequate exposure of the infecting parasite population to therapeutic concentrations of the drug (<LINK REF="REF-White-1998" TYPE="REFERENCE">White 1998</LINK>; <LINK REF="REF-Bloland-2003" TYPE="REFERENCE">Bloland 2003</LINK>). This contributes to fewer cures and parasite recrudescence, and can contribute to the development of parasite resistance to antimalarial drugs.</P>
<P>Some antimalarial drugs, such as sulfadoxine-pyrimethamine and mefloquine, require only a single dose, making the regimen straightforward. In fact, as many people attend health facilities for illness, health staff can directly supervise the dosing of these drugs. Regimens for other drugs, such as chloroquine and amodiaquine, span three days. If the drugs are acquired from a health facility the first dose can be ensured in a similar way, but subsequent doses may be missed as people usually take these at home. Children commonly receive bottles of chloroquine syrup for the treatment of malaria; adequate treatment would require caregivers to use appropriately sized dosing instruments, but this cannot always be ensured. Newly introduced courses of antimalarial treatment are increasingly complex. The WHO currently promotes artemisinin-based combination therapy (ACT) and, unless the drugs are co-formulated, this often requires people to follow the regimen for more than one antimalarial drug at a time. These regimens may be more difficult to follow correctly.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Understanding adherence</HEADING>
<P>The ability of people to follow a given treatment regimen has been studied for some time. 'Compliance', 'concordance', and 'adherence' have all been used to describe the concept. Recently, some experts have discouraged the use of the term 'compliance' as it may imply that "the patient is docile and subservient to the provider" (<LINK REF="REF-Sumartojo-1993" TYPE="REFERENCE">Sumartojo 1993</LINK>). Mullen and colleagues suggest 'concordance' may be more suitable as it reflects "the active exchange of information, negotiation, and spirit of cooperation" between patient and health provider (<LINK REF="REF-Mullen-1997" TYPE="REFERENCE">Mullen 1997</LINK>). However, it is not widely used. Haynes and colleagues believe that completing treatment is usually an independent choice of the patient and is best described as 'adherence', a statement of fact rather than of blame of the patient, prescriber, or treatment (<LINK REF="REF-Haynes-2008" TYPE="REFERENCE">Haynes 2008</LINK>). We use 'adherence' throughout this review.</P>
<P>Levels of adherence vary widely between treatments for all disease states (<LINK REF="REF-Sackett-1979" TYPE="REFERENCE">Sackett 1979</LINK>). Recorded reasons for non-adherence include adverse events, poor instructions, poor provider-patient relationship, loss of drugs, forgetting to take treatment, patient's disagreement with the need for treatment, perceived ineffectiveness of the drug, and the inability to pay for it (<LINK REF="REF-Gomes-1998" TYPE="REFERENCE">Gomes 1998</LINK>; <LINK REF="REF-Haynes-2008" TYPE="REFERENCE">Haynes 2008</LINK>). People are less likely to take medicines once they feel they have recovered from an illness (<LINK REF="REF-White-1998" TYPE="REFERENCE">White 1998</LINK>). Most interventions to promote adherence are targeted at modifying the behaviour of the patient, caregiver, or health staff (<LINK REF="REF-Volmink-1997" TYPE="REFERENCE">Volmink 1997</LINK>). Strategies include education and information campaigns, directly observed therapy, increased supervision of staff, home visits with follow up, and improved packaging of drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Drug packaging</HEADING>
<P>In a Cochrane Review, <LINK REF="REF-Haynes-2008" TYPE="REFERENCE">Haynes 2008</LINK> summarized the evidence around interventions used to help patients follow prescriptions for medications. Three trials included in the review looked at interventions with a drug-packaging component. These trials generated conflicting results. <LINK REF="REF-Henry-1999" TYPE="REFERENCE">Henry 1999</LINK> found that a package of "compliance enhancing measures" did not improve adherence or clinical outcome for <I>Helicobacter pylori</I> treatment; in fact, adherence and treatment success were high in both the control and treatment groups. Similarly, <LINK REF="REF-Becker-1986" TYPE="REFERENCE">Becker 1986</LINK> did not find any improvement in adherence or blood pressure control for hypertensive patients receiving special medication packaging. However, <LINK REF="REF-Peterson-1984" TYPE="REFERENCE">Peterson 1984</LINK> found that adherence and clinical control improved significantly in participants given a combination of "compliance-improving strategies" for the treatment of epilepsy. Another Cochrane Review <LINK REF="REF-Heneghan-2006" TYPE="REFERENCE">Heneghan 2006</LINK> has examined reminder packaging as an intervention for improving adherence to self-administered long-term medications. Eight studies were included in this review. Results were inconclusive. Whilst the intervetion appeared to improve dosing and showed the possibility for an effect on adherence, no clinical benefits of the intervention was demonstarted. The current review looks at unit-dose drug packaging as an adherence intervention for malaria treatment.</P>
<P>Historically, drugs were first packaged to preserve freshness, prevent contamination, and protect them from damage (<LINK REF="REF-Richardson-2003" TYPE="REFERENCE">Richardson 2003</LINK>). It is also an effective way to make them more recognizable, help ensure expired drugs are not used, and prevent under or over weighing and counterfeiting. Over time, marketers realized the potential of packaging to aid brand advertising. More recently, the design of packaging has been considered a useful tool to enhance adherence to treatment. Packaging can be designed to enhance communication of the regimen to patients and providers. With the aid of improved packaging, providers should be better able to give the correct amount of the drug, inform patients of the treatment regimen, and highlight the need for full therapy; and patients should be better able to use the packaging to guide treatment, even when unsupervised.</P>
<P>Some drugs have a narrow therapeutic range and must be packaged individually for each age or weight category in order to avoid under or over dosing (<LINK REF="REF-Ondari-2003" TYPE="REFERENCE">Ondari 2003</LINK>). Labelling of packs can be problematic as age estimations of mothers have frequently been found to be unreliable, and many rural villages have no weighing devices. The use of diagrams (for example, a crawling, walking or talking child used by <LINK REF="STD-Okonkwo-2001" TYPE="STUDY">Okonkwo 2001</LINK>) may be an appropriate alternative in some settings. When drugs are packaged differently, the entire range must be made available. If not, there is the risk that people may try to alter the dose by doubling (using two packs) or halving the packs they can find. This adds a new potential for miscalculations and under dosing (<LINK REF="REF-Kilian-2003" TYPE="REFERENCE">Kilian 2003</LINK>). Even when all presentations are available there is the possibility of over or under dosing at the extremes of the age range, especially among populations where malnutrition exists (<LINK REF="REF-Bloland-2003" TYPE="REFERENCE">Bloland 2003</LINK>).</P>
<P>The system of packaging adopted by each country and each pharmaceutical company varies widely. This is often due to the different and changing drug policies, various perceptions, the public and private sector involvement in drug and packaging production, and the level of technology available. Most packaging developments have been designed for use with tablets, despite children traditionally receiving syrup to treat malaria (it is considered easier to tolerate). Some investigators have developed special syrup bottles, but tablets are more readily packaged. In particular, blister packaging of tablets is becoming increasingly popular, especially with the spread of combination therapy (the two drugs can be packaged together in one blister (<LINK REF="REF-White-1999" TYPE="REFERENCE">White 1999</LINK>)). In fact, the WHO now suggests that all artemisinin-based combination treatments should be blister packed to conform to good manufacturing practice standards (<LINK REF="REF-WHO-2003" TYPE="REFERENCE">WHO 2003</LINK>). Blister packaging requires a certain level of technology and, even within this packaging type, there is great variation in the products developed. For the purpose of this review, we have extracted as much descriptive information relating to each packaging intervention as possible and attempted to relate this to any heterogeneity in the effectiveness of interventions.</P>
<P>Designs that ensure suitability for illiterate or semi-literate carers through the use of colour coding, pictures, and diagrams, as well as written instructions, should help optimize the effectiveness of interventions. One way to improve the suitability of the interventions is to consult with consumer groups at the design stage. Information from health workers often has to compete with other advice and perceptions before patients decide what to do about recommended treatments. When designing drug packaging, an understanding of the user group will help counteract any negative perspectives, reinforce positive ones, fill in missing information, answer questions, and overcome suspicion (<LINK REF="REF-Francis-1997" TYPE="REFERENCE">Francis 1997</LINK>). Many episodes of uncomplicated malaria are treated in the home after initiation at the health centre or entirely through self-treatment (<LINK REF="REF-Biritwum-2000" TYPE="REFERENCE">Biritwum 2000</LINK>; <LINK REF="REF-Kilian-2003" TYPE="REFERENCE">Kilian 2003</LINK>). People will often use drugs left over from a previous episode or will purchase them from private vendors (<LINK REF="REF-Biritwum-2000" TYPE="REFERENCE">Biritwum 2000</LINK>). In both scenarios, there will be no contact with medical facilities (<LINK REF="REF-Kilian-2003" TYPE="REFERENCE">Kilian 2003</LINK>). In these cases, innovations that do not rely on the presence of health staff will be particularly useful.</P>
<P>This review has examined the use of one specific type of packaging, unit-dose packaging. To make patients more aware of when to take each tablet, a full course of therapy is presented in a single pack, with the drugs to be taken together adjacent to each other, sometimes with markings or colours to indicate that they should be taken all at once; see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> for examples.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Analysing the effectiveness of unit-dose packaging</HEADING>
<P>In reality, unit-dose packaging is not likely to be provided as a single adherence intervention. Often, combining various interconnecting strategies helps ensure that the best patient outcomes can result (<LINK REF="REF-Haynes-1996" TYPE="REFERENCE">Haynes 1996</LINK>). This must be taken into account when analysing which interventions are successful in which settings, and when defining, developing, documenting, and reproducing the interventions.</P>
<P>In addition, any difference in malaria cure rates or adherence levels between the intervention and control groups could be due to either the intervention (unit-dose packaging) or to the non-specific effects of increased attention paid to the intervention group. Depending on where and when the drugs are acquired, some form of health education may be given alongside the provision of antimalarial drugs. With the introduction of new unit-dose packaged drugs, this health education may be more extensive and clear (structured and backed up by the pack, helping to reinforce messages). It could be that the packaging is a useful co-intervention that increases provider instruction to the patient. It may also help private sellers with little medical knowledge to give correct information. This may be the mechanism for an effect on treatment adherence and cure rates. For the purpose of this review, we have assessed the extent to which co-interventions (including information and education) have been reported and controlled for, and when "usual care" or "normal practice" was quoted as the control intervention we checked that this was adequately defined.</P>
<P>The aim of any adherence promotion in malaria treatment is to improve malaria cure rates (as measured by treatment failure), and we have used this as our primary outcome measure. Furthermore, while adherence to correct doses of malaria treatment has been found to correlate with improvement in the condition of patients (<LINK REF="STD-Okonkwo-2001" TYPE="STUDY">Okonkwo 2001</LINK>), no clear connection has been found between malaria treatment adherence and cure (and some people may be cured at less than 100% adherence). Malaria cure rate may be improved with increased adherence, but we cannot guarantee that this is the mechanism for any observed change. Ensuring optimal treatment adherence may also help slow the development of parasite drug resistance by ensuring the correct drug concentration in the blood and the quickest cure, but we have not addressed this issue in the current review. Some researchers have hypothesized that as increased adherence to treatment will mean patients receive on average a higher dose of the drug, this may lead to an increase in the incidence of some adverse events. Hence, the current review also assesses the incidence of adverse events, where reported.</P>
<P>Malaria illness can take two forms, uncomplicated malaria and severe malaria. The most common symptom of uncomplicated malaria is fever, although patients may also complain of headache, aches and pains elsewhere in the body, and occasionally of abdominal pain and diarrhoea. Severe malaria is caused by infection with <I>P. falciparum</I> and usually occurs as a result of delay in treating an uncomplicated attack of falciparum malaria (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>). This review has examined the use of unit-dose packaging for treating uncomplicated malaria only. Severe malaria is normally treated in the hospital or clinic setting with intravenous drugs; whether unit-dose packaging interventions have an effect on treatment outcomes in this setting is a different question.</P>
<P>Randomized controlled trials are rarely used to investigate complex interventions such as drug packaging. Most investigators use a community design, but it is often difficult to determine the treatment effect in this trial design. We have therefore not included community studies in this review, but we have discussed any pertinent observations made in such studies in the context of the main findings of the review.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-06-25 14:39:23 +0100" MODIFIED_BY="[Empty name]">
<P>To summarize the effects of unit-dose packaged treatment on treatment failure and treatment adherence in people with uncomplicated malaria.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-04 14:45:25 +0100" MODIFIED_BY="Anne-Marie Stephani">
<SELECTION_CRITERIA MODIFIED="2009-08-04 14:45:25 +0100" MODIFIED_BY="Anne-Marie Stephani">
<CRIT_STUDIES MODIFIED="2009-08-04 14:45:23 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>Randomized controlled trials (RCTs), and quasi-RCTs; including trials randomized by cluster.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-06-25 14:09:41 +0100" MODIFIED_BY="[Empty name]">
<P>People diagnosed (clinically or confirmed with microscopy) with uncomplicated malaria infection (as defined by the trial authors).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-08 17:57:38 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Any programme that includes unit-dose packaging of antimalarial drugs, that is, drugs packed in units of a single dose.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<P>Standard practice before the intervention, or alternative packaging intervention.</P>
<P>
<I>Intervention and control arm to receive the same antimalarial drug and any other interventions.</I>
</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-08-04 14:45:25 +0100" MODIFIED_BY="Anne-Marie Stephani">
<SUBSECTION>
<HEADING LEVEL="4">Primary</HEADING>
<UL>
<LI/>
</UL>
<P>Treatment failure on or by day 28: (1) including new infections and (2) adjusted to exclude new infections (detected by PCR).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary</HEADING>
<P>Treatment failure on or by day 14: (1) including new infections and (2) adjusted to exclude new infections (detected by polymerase chain reaction (PCR)).</P>
<P>Treatment adherence: participants completing the full treatment regimen, as approximated by the trial authors (for example, by pill counts or residual syrup measurement; patient interview; or drug concentration in urine or plasma).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<UL>
<LI>Serious adverse events (fatal, life threatening, or require hospitalization).</LI>
<LI>Adverse events that result in the discontinuation of treatment.</LI>
<LI>Any other adverse events.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-07-24 15:17:35 +0100" MODIFIED_BY="Jenny Bellorini">
<P>We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<SUBSECTION>
<HEADING LEVEL="3">Databases</HEADING>
<P>We searched the following databases using the search terms and strategy described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. Cochrane Infectious Diseases Group Specialized Register (February 2009); Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library</I> (Issue 1, 2009); MEDLINE (1966 to February 2009); EMBASE (1974 to February 2009); and LILACS (1982 to February 2009)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Conference proceedings</HEADING>
<P>We searched the following conference proceedings for relevant abstracts: The Third Multilateral Initiative on Malaria Pan-African Conference, Arusha, Tanzania, 18 to 22 November 2002; The Third European Congress on Tropical Medicine and International Health, Lisbon, Portugal, 8 to 12 September 2002; and The International Conference on Malaria: Current Status and Future Trends, Bangkok, Thailand, 16 to 19 February 2003; the Fourth Multilateral Initiative on Malaria Pan-African Conference (Roll Back Malaria), Yarounde, Cameroon, 13 to 18 November 2005; the Fifth European Congress on Tropical Medicine and International Health, Amsterdam, the Netherlands, 24 to 28 May 2007; Stop Malaria Now! (an African-European Initiative) International Malaria Conference, Bonn, Germany, 21 to 22 April 2008.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Researchers, organizations, and pharmaceutical companies</HEADING>
<P>For unpublished and ongoing studies, we contacted individual researchers working in the field, the WHO, and the pharmaceutical companies GlaxoSmithKline, Merck, and Novartis (May 2009).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reference lists</HEADING>
<P>We also checked the reference lists of all studies identified by the above methods.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-04 12:08:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-07-30 08:45:49 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>Lois Orton assessed the results of the literature search and obtained the full reports for all potentially relevant studies. Both authors independently assessed the potentially relevant studies for inclusion using an eligibility form based on the inclusion criteria. We scrutinized all potentially eligible studies for duplicate publication from the same data set, and resolved disagreements through discussion and, when necessary, by consulting a Cochrane Infectious Diseases Group Editor. We stated the reasons for excluding studies in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
<P>We described the usability of drug packaging (for literate and non-literate people) using the following criteria (seeking further information from trial authors where necessary): regimen; packaging type; labelling and instructions on pack; and dosage presentations for age or weight categories.</P>
<P>We examined each trial to identify the presence of any possible co-interventions, apart from the primary intervention. This included any health education (formal or informal), training, advice, poster, television or radio promotion, follow up, or support. We took this into consideration in the assessment of the efficacy of the primary intervention.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-07-30 08:45:52 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>Both authors independently extracted data on the methods, types of participants, interventions, and outcomes. We compared the two sets of extracted data and discussed them to ensure accuracy and completeness. Where necessary, we sought the opinion of a Cochrane Infectious Diseases Group Editor to resolve any disagreements. Where required, we requested additional data from the trial authors.</P>
<P>As packaging interventions may be complex and unique, we also extracted additional information that helps the reader to understand the specific characteristics of the intervention.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-08-04 12:08:51 +0100" MODIFIED_BY="[Empty name]">
<P>We independently assessed the methodological quality of each trial based on the guidance given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> <LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>, and using the criteria outlined below, resolving disagreements through discussion. We displayed this information in a table and described it in the '<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>'.</P>
<P>We assessed the generation of the allocation sequence and allocation concealment as adequate, inadequate, or unclear according to <LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>. We considered the completeness of outcome data to be adequate if it was greater than 80%. We classified assessor blinding (all other types of blinding are redundant with pre-packaging interventions) as present, absent, or unclear.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-07-30 08:46:20 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>We undertook a descriptive interpretation of results. We described all possible sources of heterogeneity between the interventions according to the criteria outlined above under description of intervention. Where possible, we also pooled the data in a meta-analysis using the methods described below.</P>
<P>We used Review Manager 5.0 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) to make comparisons between the treatment and control groups in an intention-to-treat analysis. We combined binary data using risk ratio (RR) and the fixed-effect model and presented them with 95% confidence intervals (CIs). We assessed heterogeneity by visually examining the forest plots and by using the Chi<SUP>2</SUP> test for heterogeneity with a 5% level of statistical significance, but detected none.</P>
<P>We will use the following planned analyses, which were not required in this version because of insufficient studies, when we update this review with new trials. (1) We will analyse continuous data using the mean difference with 95% confidence intervals. (2) If we detect statistically significant heterogeneity, and it is still appropriate to pool the data, we will use the random-effects model. (3) We will explore potential sources of heterogeneity using subgroup analyses based on the criteria outlined under description of intervention, and the proportion of participants known to have completed the full treatment regimen. (4) We will conduct sensitivity analyses on the basis of trial methodological quality (using the quality criteria outlined above) and the adequacy of reporting of co-interventions (in particular, whether or not it was explicitly verified that an equal level of concomitant health education was provided in the intervention and control arms of the trial). (5) We will consider publication bias using a funnel plot.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-07-30 09:18:23 +0100" MODIFIED_BY="Anne-Marie Stephani">
<STUDY_DESCRIPTION MODIFIED="2009-07-30 09:18:23 +0100" MODIFIED_BY="Anne-Marie Stephani">
<SEARCH_RESULTS MODIFIED="2009-07-30 08:46:25 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>We identified 57 articles from the search strategy and excluded 45 after scanning the titles. The remaining 12 papers reported 13 potentially relevant studies, of which eight did not meet the inclusion criteria (<I>see</I> <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Five trials met our inclusion criteria (<LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>; <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>; <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK>; <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK>; <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK>); they are detailed in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and summarized below.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-07-30 09:18:23 +0100" MODIFIED_BY="Anne-Marie Stephani">
<SUBSECTION>
<HEADING LEVEL="4">Trial design and location</HEADING>
<P>
<LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> did not state the method of randomization used; <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>, <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>, and <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> used alternate allocation techniques to allocate individuals, and <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> randomized health facilities (cluster-randomization). <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK> and <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> were conducted in Health and Epidemic Prevention Stations in Hunan Province, China, where malaria transmission is epidemic, with migration allowing imported cases. <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> was conducted in Papua New Guinea where malaria transmission is high and perennial. The other trials were conducted in Ghana: <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> in Cape Coast, where malaria is highly endemic and perennial; and <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> in Wenchi District, where malaria transmission is intense and stable with slight seasonal variation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">RCTs</HEADING>
<P>
<LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> randomized 203 adults with clinically and microscopically confirmed malaria into three treatment groups. We have excluded one treatment group because participants did not receive the same counselling co-intervention as the other groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quasi-RCTs</HEADING>
<P>
<LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> randomized 299 children with clinically confirmed malaria to two treatment groups. <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK> and <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> randomized 596 adults with slide-confirmed <I>P. vivax</I> malaria to two treatment groups. <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> was conducted two years later in the same region as <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>, but when we contacted the trialists, they clarified that no participant was included in both trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cluster-RCT</HEADING>
<P>
<LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> randomized six health facilities into two treatment groups. At these facilities, 616 children and adults with clinical malaria were recruited. Participants up to six years were given syrup, and those over six years received tablets. We have only included data for the 319 participants who received tablets, as the syrup was not unit-dose packaged.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>
<LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK> and <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> provided labelled and boxed blister packs of chloroquine and primaquine tablets and capsules; <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK>, <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> and <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> provided simple labelled and sectioned polythene bags of chloroquine tablets (<LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK>; <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK>, see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) or chloroquine and sulphadoxine-pyrimethamine tablets (<LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK>). In <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>, <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>, and <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> control participants received tablets or capsules in paper envelopes or loose, while in <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> control participants received chloroquine syrup in bottles and in <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> control participants received chloroquine and sulphadoxine-pyrimethamine tablets in separate polythene bags with pen-written instructions.</P>
<P>
<LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> trained prescribers in using a chart, showing the appropriate dosage by weight, to demonstrate to caregivers how to give the medicine. <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> trained intervention and control facility staff in prescribing and dispensing; all participants were given the same counselling in how to take the drug, but participants at the intervention facilities were given additional counselling. <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK> trained staff to give similar oral instructions at the intervention and control facilities. <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> provided staff with a written script containing information, questions, and special instruction including information on the risks associated with malaria if it was not quickly and appropriately treated, and on the need to adhere to medication directions, to complete treatment, to seek further medical attention if adverse effects were experienced, and to return to the hospital if there was no improvement after completion of the medication. <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> did not provide any data about staff training or patient information. Participants were given the drugs to take at home in <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK> and <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>; in <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> they were observed taking the first dose at the health centre; and in <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> and <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> it is unclear where participants took the drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>None of the trials reported on the primary outcome measure, treatment failure, as defined in the inclusion criteria. Instead, <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK> tested for parasitaemia and clinical symptoms at day nine (eight-day regimen), <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> reported cure according to medical notes (undefined) and participants' perception at day four of a three-day regimen, and <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> and <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> assessed wellness of the child at day four (three-day regimen). Measurements taken at such early time points will not pick up relapses and recrudescence of infection. In an attempt to overcome this, <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> followed a subset of 57 participants to day 100. All five trials measured treatment adherence (which they termed "compliance") through participant interview. <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> also measured the remaining drugs at the end of the treatment course, and <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> marked the drugs with phenobarbital and measured its level in the blood as an indicator of treatment adherence.</P>
<P>
<LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> and <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> recorded some adverse events, while <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>, <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>, and <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> did not measure the incidence of adverse events.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-30 08:47:02 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>See the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' for details about the methodology, and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for the risk of bias assessment.</P>
<P>Only the cluster-RCT, <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK>, used an adequate method to <B>generate the allocation sequence</B>. The three quasi-RCTs, <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>, <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>, and <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK>, used alternate allocation, and <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> did not state the method used. None of the trials provide any details of the method of <B>allocation concealment</B>, although allocation was not likely to have been concealed in the quasi-RCTs as the method of alternate allocation would lead to a predictable allocation sequence. The outcome assessor was not <B>blinded</B> in any of the trials (trialists provided additional data for <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK> and <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>). It was not possible to blind participants or healthcare providers in <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> but, as the health facilities were far apart and communication was not good, it is unlikely that treatment allocation would influence participants in their choice of facility (intervention or control).<I> </I>It was only possible to calculate the <B>completeness of outcome data for two</B> of the trials, <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> and <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK>. <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> included 99% of the participants in the analysis, which we considered to be adequate, and <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> included 73%, which we considered to be inadequate.</P>
<P>The cluster-RCT, <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK>, used three intervention and three control groups and treated the data as if it came from a trial that randomized individuals (not taking account of the clustering). As participants recruited at the same facility are likely to be more similar than participants recruited at different facilities, there is likely to be a high level of correlation between trial participants, which the trialists have not evaluated or considered.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-07-30 08:47:26 +0100" MODIFIED_BY="Anne-Marie Stephani">
<SUBSECTION>
<HEADING LEVEL="3">Blister packs versus paper envelopes: 596 participants, two quasi-RCTs</HEADING>
<P>Although the trials did not assess <B>treatment failure</B>, <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK> found that all 324 participants (intervention and control) were aparasitaemic and asymptomatic at day nine of an eight-day regimen, and <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> found that one of the 57 participants still available for follow up at day 100 had recrudesced at day 88 (control group; reported not to have completed treatment).</P>
<P>A combined estimate from the two trials found that 18% more participants in the group using blister packs reported that they <B>adhered to the full regimen</B> (measured by participant interview), which is statistically significant (RR 1.18, 95% CI 1.12 to 1.25; 596 participants; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> analysed the data separately for each drug and found a statistically significant difference, in favour of the intervention, in both drug groups (chloroquine 67/69 versus 56/67, P value &lt; 0.05; primaquine 67/69 versus 49/67, P value 0.05; trialists' values). <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> also measured drug marker levels and found no statistically significant difference in the median phenobarbital level-to-dose ratio between the intervention and control groups (trialists' data; <I>see </I>
<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sectioned polythene bags versus bottled syrup: 299 participants, one quasi-RCT</HEADING>
<P>
<LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> did not measure <B>treatment failure</B>, but by day four of the three-day regimen most participants were considered fully recovered by their caregivers (intervention 144/155 versus control 137/144).</P>
<P>Participant-reported <B>treatment adherence </B>(measured by participant interview) was 115% higher in those receiving tablets in sectioned polythene bags than in those receiving bottles of syrup (RR 2.15, 95% CI 1.76 to 2.61; 299 participants; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The volume of the instrument used to dispense the syrup to control participants was not considered in the assessment of adherence. This was found to vary from 1 ml to 9 ml, and most were less than the recommended 5 ml; when the trialists took spoon volume into account, only 12/140 of the control participants had taken the recommended 25 mg/kg total dose by day four, but not necessarily according to the prescribed dosage schedule.</P>
<P>The trialists did not collect <B>adverse event</B> data systematically. Of the 155 participants receiving tablets, 28 vomited some medication and six vomited all tablets. The trialists reported that if those participants who vomited their tablets were considered non-adherent, the difference in adherence between intervention and control is still statistically significant (76% versus 42%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sectioned polythene bags versus paper envelopes: six clusters, one cluster-RCT</HEADING>
<P>
<LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> did not assess <B>treatment failure</B>, but they reported that most participants' wellness had improved by day four of the three-day regimen (intervention: 152 improved, 13 unchanged, two worsened; control: 143 improved, four unchanged, five worsened).</P>
<P>
<B>Treatment adherence</B> (measured by participant interview and drug inspection) was higher in the group receiving tablets in sectioned polythene bags than in those receiving tablets in paper envelopes (137/167 intervention versus 92/152 control). Although reported as statistically significant, the trialists analysed the data without taking account of clustering, so the true result may not be.</P>
<P>The<B> </B>trialists<B> </B>reported a similar incidence of itching, dizziness, and other <B>adverse events</B>. They did not collect these data systematically, but reported them when given as a reason for not taking the drugs as recommended (<I>see </I>
<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sectioned polythene bags versus polythene bags (unsectioned)</HEADING>
<P>
<LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK> did not assess <B>treatment failure</B>, but reported no significant difference in the cure rate at day four (intervention 77/91 versus control 96/112).</P>
<P>There was no statistically significant difference in<B> treatment adherence </B>between treatment groups (measured by participant interview; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). However, the authors found both intervention and control group participants to have better adherence than a further control group which received neither packaging nor counselling.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-08-04 12:10:34 +0100" MODIFIED_BY="[Empty name]">
<P>There is insufficient good quality evidence to determine the effect of unit-dose packaged antimalarial drugs on treatment failure, but five small trials suggest that some designs may improve adherence to treatment for uncomplicated malaria when supported by prescriber training and patient information. However, the reliability of these conclusions is limited by the methodological quality of the trials that inform it.</P>
<P>Of the five RCTs that met our inclusion criteria, we were only able to calculate the number of randomized participants included in the analysis for two of them. Four used an inadequate or unclear method of allocation sequence generation, and the other randomized health facilities rather than patients. This cluster-RCT included only a small number of health facilities, which reduces the statistical power of the trial, as it is likely that data for participants recruited at the same treatment facility will be more correlated than data for participants recruited at different facilities. In fact, the trialists ignored the possibility that data for participants were correlated in the analyses and, as such, this trial may overestimate the treatment effect. None of the trials blinded the outcome assessor, and it is likely that most trials did not conceal allocation of treatment, which allows the potential for bias. While there are limitations in the interpretation of the results of the included trials, they are supported by some observational studies that also suggest an improvement in adherence with the introduction of packaged antimalarial drugs (<LINK REF="STD-Browne-2001" TYPE="STUDY">Browne 2001</LINK>; <LINK REF="STD-Sirima-2003" TYPE="STUDY">Sirima 2003</LINK>).</P>
<P>Patient interview was the predominant method used to approximate treatment adherence in the included trials (one trialist verified this measure by inspecting left-over drugs). This is subject to bias, as participants will not always recall accurately how they took the drug. Another way to estimate what treatment was taken is to measure drug concentrations in the blood. However, this only provides a snap shot of medication taking. Reliable approaches to measuring treatment adherence are needed in order to assess the effects of adherence interventions accurately, such as unit-dose packaging.</P>
<P>Most of the included trials assessed treatment adherence in terms of the participants drug-taking behaviour in relation to the treatment guidelines. Although efforts were made by the trial authors to verify that prescribers were also adhering to the treatment guidelines this is difficult to ensure and, therefore, non-adherence could be due to either prescriber or patient error. <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK> looked at prescribers' ability to adhere to treatment guidelines and found that despite a background training session conducted for all prescribers (at intervention and control facilities), more participants at the intervention facilities were prescribed the correct doses. This suggests that unit-dose packaging interventions help both the prescriber and the patient.</P>
<P>Some investigators have developed interventions for packaging paediatric syrup by adding dosing diagrams and spoons (<LINK REF="STD-Okonkwo-2001" TYPE="STUDY">Okonkwo 2001</LINK>; <LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK>), but at present no unit-dose style packaging has been developed for syrup. Others have begun examining the use of unit-dose packaged tablets for children instead. <LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK> compared unit-dose packaged tablets with bottled syrup, and found a large improvement in adherence. The increased ease of dosage due to a change from syrup to tablets will probably have played a large part in the observed effect in this trial. The caregivers involved in this trial accepted and even preferred tablets for their children (<LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK>). There was a slight problem with some children vomiting tablets. Investigators addressed this concern by suggesting caregivers crush and mix the tablets with sugar. However, as <LINK REF="REF-Standing-2004" TYPE="REFERENCE">Standing 2004</LINK> asserts, it has not been shown that this method adequately delivers the drug, especially as the tablets have also been snapped in order to dose the children correctly. This is known to lead to wastage. One way to overcome this problem may be to manufacture special paediatric formulations, or to focus efforts on helping mothers to dose syrup correctly.</P>
<P>The design of packaging interventions, and the context in which they are used, is diverse and care should be taken when generalizing conclusions about their effectiveness from one design to another or from one region to another. Good drug-packaging design is informed by users' needs. Qualitative investigation has shown that unit-dose packaged drugs are generally acceptable or even preferred (<LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK>), but further studies should help determine the most effective design and elucidate which co-interventions help maximize this effectiveness within and between treatment settings. Prescriber training and patient information is likely to be a critical factor in how well such interventions work in practice. In these trials, while it was usually intended for staff at the intervention and control facilities to receive comparable levels of training, it often transpired that staff at the intervention facilities received more comprehensive training and therefore gave the patients more comprehensive information. It is likely that the pack was used to guide the information given to patients. It was new and had to be explained. In fact, the <LINK REF="STD-Okonkwo-2001" TYPE="STUDY">Okonkwo 2001</LINK> trial found a significant difference in adherence between packaged drugs with verbal instructions and packaged drugs without verbal instructions (packaging not unit dose in this trial).</P>
<P>Normal practice circumstances are likely to differ dramatically from trial conditions. All trials included in this review were conducted intensively in a small locality, using a small number of government health facilities. Most prescribers were fairly highly qualified and were given training in how to dispense the unit-dose packaged drugs with information to help patients take them correctly. If interventions such as these are going to be used in a wider setting, for example with multinationals producing packs on a large scale, the same level of one-to-one training is not likely to be provided to prescribers and dispensers, and the packs will have to work in a variety of settings in which they are unlikely to have been tested.</P>
<P>There is also the challenge of designing packs that can be used effectively in more rural settings. Here, drugs are more likely to be distributed by unregulated (normally unqualified) private drug vendors. In fact, some episodes of malaria will be treated in the home using leftover drugs without any contact with a health facility or drug vendor. In both of these situations, the packs will either have to be designed to stand alone (with no supportive co-interventions) or shopkeepers will have to be trained in dispensing. As it is not always possible to ensure a good level of prescriber-patient information, sector-wide supportive interventions may be a useful tool to help increase the general awareness of unit-dose packaged drugs (<LINK REF="REF-Marsh-2004" TYPE="REFERENCE">Marsh 2004</LINK>). The WHO has recognized this and are preparing recommendations that packaged drugs be given as part of wider Information, Education, and Communication campaigns involving, for example, schools, printed posters, and television (<LINK REF="STD-Browne-2001" TYPE="STUDY">Browne 2001</LINK>).</P>
<P>We have found only five trials investigating the unit-dose packaging of malaria treatment. These trials all used chloroquine-based therapies, regimens which are no longer recommended for use in the treatment of uncomplicated falciparum malaria (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>). While all trials appear to show an increase in participant-reported adherence with unit-dose packaged drugs, they did not demonstrate an effect on treatment effectiveness and patient outcomes. Three of the four included trials used combination therapy (chloroquine-based) (<LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>; <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>; <LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK>). However, in <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK> and <LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK> the investigators did not optimize the potential of the packaging by presenting the drugs together in one pack. With the spread of multiple-drug resistant malaria, it would be useful to know how effective unit-dose packaging is when used with the currently recommended artemisinin-based combination therapies (ACTs). As the majority of deaths due to malaria occur in children aged five years and under, efforts should be targeted at developing paediatric packs.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Trials of unit-dose packaged antimalarial drugs have not assessed treatment failure. When supported by prescriber training and patient information, some package designs appear to improve participant-reported treatment adherence in the settings in which they have been tested. However, some methodological limitations of the included trials should be taken into consideration when interpreting these findings.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Unit-dose packaging interventions are complex interventions. Qualitative investigations could help determine the most reproducible and the most effective designs. Ideally, packs should be developed with input from the local community, with due consideration for the settings in which they will be employed and the need for any additional interventions (such as educational programmes) to help optimize their effectiveness. </P>
<P>Good quality RCTs of unit-dose packaged combination therapies for malaria, particularly of formulations for children under five, are urgently needed. Investigators should assess treatment failure and adverse events, not just treatment adherence. There is a need to develop reliable methods of estimating treatment adherence in these trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None stated.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-07-30 08:47:47 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>Guy Barnish was involved in one of the included trials, however he knows of no conflicts of interest. Lois Orton has no known conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-07-30 08:47:42 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>Lois Orton extracted and analysed data and drafted the review. Guy Barnish extracted data and commented on the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-07-30 08:47:55 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>2005, Issue 2 (first review version): (1) Title: changed from 'Pre-packaged drugs for treating malaria' to 'Unit-dose packaged drugs for treating malaria' for a more specific definition of the intervention. (2) Types of intervention: different drug formulations may now be used in the intervention and control arms, as these may form useful comparisons, but we will not combine the data with data from studies using the same formulation in intervention and control arms. (3) Types of outcomes: treatment failure outcome measures altered to conform to new standards; this involved removing "parasite failure rate" and replacing "early" and "late" treatment failure with treatment failure on or by day 14/28. (4) Methods of the review: inclusion of 80% of all randomized participants considered adequate, rather than 90%, to take into account the difficulty in carrying out studies of this type of intervention.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-08-04 12:26:19 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-07-30 08:48:54 +0100" MODIFIED_BY="Anne-Marie Stephani">
<INCLUDED_STUDIES MODIFIED="2009-07-30 08:48:54 +0100" MODIFIED_BY="Anne-Marie Stephani">
<STUDY DATA_SOURCE="PUB" ID="STD-Ansah-2003" NAME="Ansah 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ansah EK, Gyapong JO, Agyepong IA, Evans DB</AU>
<TI>Improving adherence to malaria treatment for children: the use of pre-packed chloroquine tablets vs. chloroquine syrup</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>7</NO>
<PG>496-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lauwo-2006" MODIFIED="2009-07-30 08:48:54 +0100" MODIFIED_BY="Anne-Marie Stephani" NAME="Lauwo 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-30 08:48:54 +0100" MODIFIED_BY="Anne-Marie Stephani" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lauwo JAK, Hombhanje FW, Tulo SP, Maibani G, Bjorge S</AU>
<TI>Impact of pre-packaging antimalarial drugs and counselling on compliance with malaria treatment at Port Moresby General Hospital Adult Outpatient Department</TI>
<SO>Papua New Guinea Medical Journal</SO>
<YR>2006</YR>
<VL>49</VL>
<PG>14-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Li-1998a" NAME="Li 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Q, Duan J, Tang L, Zhang X, Liang J, Hay A, et al</AU>
<TI>The effect of drug packaging on patients' compliance with treatment for Plasmodium vivax malaria in China</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1998</YR>
<VL>76 Suppl 1</VL>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Li-1998b" NAME="Li 1998b" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Q, Duan J, Tang L, Zhang X, Liang J, Hay A, et al</AU>
<TI>The effect of drug packaging on patients' compliance with treatment for Plasmodium vivax malaria in China</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1998</YR>
<VL>76 Suppl 1</VL>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Yeboah_x002d_Antwi-2001" NAME="Yeboah-Antwi 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeboah-Antwi K, Gyapong JO, Asare IK, Barnish G, Evans DB, Adjei S</AU>
<TI>Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2001</YR>
<VL>79</VL>
<NO>5</NO>
<PG>394-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Agyepong-2002" NAME="Agyepong 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agyepong IA, Ansah E, Gyapong M, Adjei S, Barnish G, Evans D</AU>
<TI>Strategies to improve adherence to recommended chloroquine treatment regimes: a quasi-experiment in the context of integrated primary health care delivery in Ghana</TI>
<SO>Social Science &amp; Medicine</SO>
<YR>2002</YR>
<VL>55</VL>
<PG>2215-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Browne-2001" NAME="Browne 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Browne ENL, Hall-Baidu D, Sangber-Dery F, Owusu-Antwi F</AU>
<TI>Early appropriate management of fevers in children aged 6 months to 6 years in Ghana [unpublished]</TI>
<SO>World Health Organization TDR PROJECT No. 990614</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cullinan-1997" NAME="Cullinan 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cullinan TR, Pieterick C</AU>
<TI>Packaged treatment for first-line care in cerebral malaria and meningitis</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1998</YR>
<VL>76</VL>
<NO>3</NO>
<PG>257-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krudsood-2002" NAME="Krudsood 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krudsood S, Looareesuwan S, Silachamroon U, Chalermrut K, Pittrow D, Canbon N, et al</AU>
<TI>Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2002</YR>
<VL>67</VL>
<NO>5</NO>
<PG>465-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okonkwo-2001" NAME="Okonkwo 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okonkwo PO, Akpala CO, Okafor HU, Mbah AU, Nwaiwu O</AU>
<TI>Compliance to correct dose of chloroquine in uncomplicated malaria correlates with improvement in the condition of rural Nigerian children</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>3</NO>
<PG>320-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagnoni-1997" NAME="Pagnoni 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pagnoni F, Convelbo N, Tiendrebeogo J, Cousens S, Esposito F</AU>
<TI>A community-based programme to provide prompt and adequate treatment of presumptive malaria in children</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>91</VL>
<NO>5</NO>
<PG>512-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shwe-1998" NAME="Shwe 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shwe T, Lwin M, Aung S</AU>
<TI>Influence of blister packaging on the efficacy of artesunate + mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1998</YR>
<VL>76 Suppl 1</VL>
<PG>35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sirima-2003" NAME="Sirima 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirima SB, Konate A, Tiono AB, Convelbo N, Cousens S, Pagnoni F</AU>
<TI>Early treatment of childhood fevers with pre-packaged antimalarial drugs in the home reduces severe malaria morbidity in Burkina Faso</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>2</NO>
<PG>133-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-08-04 12:26:19 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-08-04 12:26:19 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alderson-2004" NAME="Alderson 2004" TYPE="OTHER">
<AU>Alderson P, Green S, Higgins J, editors</AU>
<TI>Highly sensitive search strategy for identifying reports of randomized controlled trials in MEDLINE. Cochrane Reviewers' Handbook 4.2.2 [Updated March 2004]; Appendix 5b</TI>
<SO>http://www.cochrane.org/resources/handbook/hbook.htm</SO>
<YR>(accessed 25 January 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becker-1986" NAME="Becker 1986" TYPE="JOURNAL_ARTICLE">
<AU>Becker LA, Glanz K, Sobel E, Mossey J, Zinn SL, Knott KA</AU>
<TI>A randomized trial of special packaging of antihypertensive medications</TI>
<SO>Journal of Family Practice</SO>
<YR>1986</YR>
<VL>22</VL>
<NO>4</NO>
<PG>357-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Biritwum-2000" NAME="Biritwum 2000" TYPE="JOURNAL_ARTICLE">
<AU>Biritwum RB, Welbeck J, Barnish G</AU>
<TI>Incidence and management of malaria in two communities of different socio-economic level, in Accra, Ghana</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>8</NO>
<PG>771-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bloland-2003" NAME="Bloland 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bloland PB, Kachur SP, Williams HA</AU>
<TI>Trends in antimalarial drug deployment in sub-Saharan Africa</TI>
<SO>The Journal of Experimental Biology</SO>
<YR>2003</YR>
<VL>206</VL>
<NO>21</NO>
<PG>3761-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Francis-1997" NAME="Francis 1997" TYPE="OTHER">
<AU>Francis F</AU>
<TI>The packaging of anti-malarials in Africa: communication issues [oral presentation]</TI>
<SO>The Tropical Diseases and Health Sector Reform Task Force Meeting, 10-12 September 1997, Liverpool</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gomes-1998" NAME="Gomes 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gomes M, Wayling S, Pang L</AU>
<TI>Interventions to improve the use of antimalarials in south-east Asia: an overview</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1998</YR>
<VL>76 Suppl 1</VL>
<PG>9-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-1996" NAME="Haynes 1996" TYPE="JOURNAL_ARTICLE">
<AU>Haynes RB, McKibbon KA, Kanani R</AU>
<TI>Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9024</NO>
<PG>383-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-2008" MODIFIED="2009-07-30 08:49:49 +0100" MODIFIED_BY="Anne-Marie Stephani" NAME="Haynes 2008" TYPE="COCHRANE_REVIEW">
<AU>Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X</AU>
<TI>Interventions for enhancing medication adherence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-07-24 15:09:04 +0100" MODIFIED_BY="Jenny Bellorini">
<IDENTIFIER MODIFIED="2009-07-24 15:09:04 +0100" MODIFIED_BY="Jenny Bellorini" TYPE="DOI" VALUE="Art. No.: CD000011. DOI: 10.1002/14651858.CD000011.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heneghan-2006" MODIFIED="2009-08-04 12:26:19 +0100" MODIFIED_BY="[Empty name]" NAME="Heneghan 2006" TYPE="COCHRANE_REVIEW">
<AU>Heneghan CJ, Glasziou PP, Perera R</AU>
<TI>Reminder packaging for improving adherence to self-administered long-term medications</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>Issue 1</NO>
<IDENTIFIERS MODIFIED="2009-08-04 12:26:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-04 12:26:19 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005025.pub2."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henry-1999" MODIFIED="2008-11-08 18:15:51 +0000" MODIFIED_BY="[Empty name]" NAME="Henry 1999" TYPE="JOURNAL_ARTICLE">
<AU>Henry A, Batey RG</AU>
<TI>Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>3</NO>
<PG>811-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-08-04 12:07:25 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1</SO>
<YR>2008</YR>
<EN>[Updated September 2008]</EN>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" MODIFIED="2009-07-30 08:50:06 +0100" MODIFIED_BY="Anne-Marie Stephani" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kilian-2003" NAME="Kilian 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kilian AHD, Tindyebwa D, Gulck T, Byamukama W, Rubaale T, Kabagambe G, et al</AU>
<TI>Attitude of women in western Uganda towards pre-packed, unit-dosed malaria treatment for children</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>5</NO>
<PG>431-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marsh-2004" MODIFIED="2009-08-04 11:28:27 +0100" MODIFIED_BY="Anne-Marie Stephani" NAME="Marsh 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marsh VM, Mutemi WM, Willetts A, Bayah K, Were S, Ross A, et al</AU>
<TI>Improving malaria home treatment by training drug retailers in rural Kenya</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>4</NO>
<PG>451-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mullen-1997" NAME="Mullen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Mullen PD</AU>
<TI>Compliance becomes concordance</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<NO>7082</NO>
<PG>691-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ondari-2003" NAME="Ondari 2003" TYPE="CORRESPONDENCE">
<AU>Ondari C</AU>
<SO>Personal communication</SO>
<YR>20 March 2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peterson-1984" NAME="Peterson 1984" TYPE="JOURNAL_ARTICLE">
<AU>Peterson GM, McLean S, Millingen KS</AU>
<TI>A randomised trial of strategies to improve patient compliance with anticonvulsant therapy</TI>
<SO>Epilepsia</SO>
<YR>1984</YR>
<VL>25</VL>
<NO>4</NO>
<PG>412-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2009-07-30 08:51:14 +0100" MODIFIED_BY="Anne-Marie Stephani" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richardson-2003" NAME="Richardson 2003" TYPE="OTHER">
<AU>Richardson &amp; Edwards, Inc</AU>
<TI>A brief history of packaging</TI>
<SO>www.richanded.com/html/packaging_history.htm</SO>
<YR>(accessed 18 September 2003)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sackett-1979" NAME="Sackett 1979" TYPE="BOOK_SECTION">
<AU>Sackett DL, Snow JC</AU>
<TI>The magnitude of adherence and nonadherence</TI>
<SO>Compliance in health care</SO>
<YR>1979</YR>
<PG>11-22</PG>
<ED>Haynes RB, Taylor DW, Sackett DL</ED>
<PB>John Hopkins University Press</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Standing-2004" NAME="Standing 2004" TYPE="JOURNAL_ARTICLE">
<AU>Standing JF, Wong ICK</AU>
<TI>Chlorproguanil-dapsone for malaria</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<NO>9447</NO>
<PG>1752-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sumartojo-1993" NAME="Sumartojo 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sumartojo E</AU>
<TI>When tuberculosis treatment fails. A social behavioural account of patient adherence</TI>
<SO>American Review of Respiratory Diseases</SO>
<YR>1993</YR>
<VL>147</VL>
<NO>5</NO>
<PG>1311-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volmink-1997" NAME="Volmink 1997" TYPE="JOURNAL_ARTICLE">
<AU>Volmink J, Garner P</AU>
<TI>Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7120</NO>
<PG>1403-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-1998" NAME="White 1998" TYPE="JOURNAL_ARTICLE">
<AU>White NJ</AU>
<TI>Why is it that antimalarial drug treatments do not always work?</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>4</NO>
<PG>449-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-1999" NAME="White 1999" TYPE="JOURNAL_ARTICLE">
<AU>White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al</AU>
<TI>Averting a malaria disaster</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9168</NO>
<PG>1965-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1993" NAME="WHO 1993" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>A global strategy for malaria for malaria control</SO>
<YR>1993</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000" NAME="WHO 2000" TYPE="BOOK">
<AU>World Health Organization, Gilles HM</AU>
<SO>Management of severe malaria: a practical handbook</SO>
<YR>2000</YR>
<EN>2nd</EN>
<PB>Geneva</PB>
<CY>World Health Organization</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2003" NAME="WHO 2003" TYPE="OTHER">
<AU>Malaria Control Department, World Health Organization</AU>
<TI>An update on quality assurance and procurement through WHO for improving access to artemisinin-based combination treatments (ACTs) for malaria</TI>
<SO>http://www.paho.org/English/AD/DPC/CD/mal-acts-update-7-03.pdf</SO>
<YR>2003 (accessed 11 November 2003)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2004" MODIFIED="2009-07-30 08:51:51 +0100" MODIFIED_BY="Anne-Marie Stephani" NAME="WHO 2004" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>The world health report 2004: changing history</SO>
<YR>2004</YR>
<PB>Geneva</PB>
<CY>World Health Organization</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" MODIFIED="2009-07-30 08:51:35 +0100" MODIFIED_BY="Anne-Marie Stephani" NAME="WHO 2006" TYPE="OTHER">
<TI>World Health Organization</TI>
<SO>Guidelines for the treatment of malaria</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-07-30 08:52:33 +0100" MODIFIED_BY="Anne-Marie Stephani">
<REFERENCE ID="REF-Orton-2005" MODIFIED="2009-07-30 08:52:33 +0100" MODIFIED_BY="Anne-Marie Stephani" NAME="Orton 2005" TYPE="COCHRANE_REVIEW">
<AU>Orton L, Barnish G</AU>
<TI>Unit-dose packaged drugs for treating malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-07-24 15:13:21 +0100" MODIFIED_BY="Jenny Bellorini">
<IDENTIFIER MODIFIED="2009-07-24 15:13:21 +0100" MODIFIED_BY="Jenny Bellorini" TYPE="DOI" VALUE="Art. No.: CD004614. DOI: 10.1002/14651858.CD004614.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-30 08:48:02 +0100" MODIFIED_BY="Anne-Marie Stephani">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-07-30 08:48:02 +0100" MODIFIED_BY="Anne-Marie Stephani" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-05-30 17:12:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ansah-2003">
<CHAR_METHODS MODIFIED="2009-05-30 17:12:05 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized controlled trial</P>
<P>Generation of allocation sequence: alternate allocation</P>
<P>Allocation concealment: no information provided</P>
<P>Blinding of outcome assessor: none</P>
<P>Completeness of outcome data: 99%<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-04 13:53:41 +0000" MODIFIED_BY="[Empty name]">
<P>Participants: 299 analysed (155 intervention; 144 control); 301 initially recruited</P>
<P>Inclusion criteria: aged 0 to 5 years; brought to 1 of 2 clinics with malaria</P>
<P>Exclusion criteria: none given, but 2 participants excluded on developing severe malaria</P>
<P>Mean age: not stated</P>
<P>Age range: not stated</P>
<P>Male to female ratio: not stated</P>
<P>Education: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 18:13:06 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for details</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-04 13:54:32 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Treatment adherence: number of participants following the prescribers' exact instructions in terms of dosage (spoon size for syrup not taken into account), frequency of daily administration, and duration of treatment; measured by participant interview</LI>
<LI>Caregivers' assessment of wellness at day 4</LI>
<LI>Vomiting of tablets</LI>
</OL>
<P>Not included in review:</P>
<OL>
<LI>Packaging acceptability and preference</LI>
<LI>Financial and economic costs</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-10 16:33:54 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Cape Coast, Ghana</P>
<P>Health facilities: 2 public health centres</P>
<P>Endemicity: highly endemic malaria</P>
<P>Antimalarial drug resistance: not stated</P>
<P>Malaria diagnosis: clinical (<I>Plasmodium falciparum </I>causes most morbidity and mortality in this area)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-30 08:48:00 +0100" MODIFIED_BY="Anne-Marie Stephani" STUDY_ID="STD-Lauwo-2006">
<CHAR_METHODS MODIFIED="2009-05-30 17:12:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: no information provided</P>
<P>Blinding of outcome assessor: none</P>
<P>Completeness of outcome data: 73%<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 08:48:00 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>Participants: 103 analysed (91 intervention; 112 control); 180 initially recruited</P>
<P>Inclusion criteria: adult; clinical and microscopic diagnosis of malaria; prescribed standard antimalarial drugs; spoken and understood English, Tok Pisin or Motu</P>
<P>Exclusion criteria: inability to return for follow-up interview on day 4</P>
<P>Mean age: not stated</P>
<P>Age range: not stated</P>
<P>Male to female ratio: 242:194</P>
<P>Education: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-10 16:37:57 +0100" MODIFIED_BY="[Empty name]">
<P>see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for details</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 15:03:46 +0100" MODIFIED_BY="Jenny Bellorini">
<P>1. Treatment failure at day 4<BR/>2. Treatment adherence at day 4: interview - good adherence if remember instructions and complete medication as prescribed or directed</P>
<P>Not included in review:</P>
<P>3. Health professionals' reactions to the packaging</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 08:48:00 +0100" MODIFIED_BY="Anne-Marie Stephani">
<P>Location: Port Moresby, Papua New Guinea</P>
<P>Health facilities: outpatient department of Port Moresby General Hospital</P>
<P>Endemicity: not stated</P>
<P>Antimalarial drug resistance: chloroquine and amodiaquine</P>
<P>Malaria diagnosis: clinical and microscopic<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 15:04:22 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Li-1998a">
<CHAR_METHODS MODIFIED="2009-05-30 17:12:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized controlled trial</P>
<P>Generation of allocation sequence: alternate allocation</P>
<P>Allocation concealment: no information provided</P>
<P>Blinding of outcome assessor: none</P>
<P>Completeness of outcome data: number analysed provided but number recruited not provided<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 15:04:16 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Participants: 324 analysed (161 intervention; 163 control); no data provided on how many participants were initially recruited</P>
<P>Inclusion criteria: slide positive for <I>Plasmodium vivax</I> malaria; aged &gt; 15 years; ambulatory</P>
<P>Exclusion criteria: major clinical symptoms requiring hospitalization; malaria treatment in the previous 6 months</P>
<P>Mean age: 31 years</P>
<P>Age range: 16 to 63 years</P>
<P>Male to female ratio: 300:24</P>
<P>Education: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 18:13:06 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for details</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-04 13:55:44 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Treatment adherence: number of participants completing full treatment; measured by participant interview</LI>
<LI>Participants tested for parasitaemia at day 9</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 15:04:22 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Location: Hunan province, China</P>
<P>Health facilities: staff highly qualified, each station had good working relationship with provincial authorities</P>
<P>Endemicity: epidemic (imported) malaria</P>
<P>Antimalarial drug resistance: not stated</P>
<P>Malaria diagnosis: microscopically confirmed <I>Plasmodium vivax</I> malaria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 15:04:45 +0100" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Li-1998b">
<CHAR_METHODS MODIFIED="2009-05-30 17:13:03 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized controlled trial</P>
<P>Generation of allocation sequence: alternate allocation</P>
<P>Allocation concealment: no information provided</P>
<P>Blinding of outcome assessor: none</P>
<P>Completeness of outcome data: number analysed provided but number recruited not provided<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 15:04:38 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Participants: 272 analysed (138 intervention; 134 control); no information provided on the number of participants initially recruited</P>
<P>Inclusion criteria: slide positive for <I>Plasmodium vivax</I> malaria; aged &gt; 15 years; ambulatory</P>
<P>Exclusion criteria: major clinical symptoms requiring hospitalization; malaria treatment in the previous 6 months</P>
<P>Mean age: not stated</P>
<P>Age range: 11 to 67 years</P>
<P>Male to female ratio: mostly male</P>
<P>Education: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 18:13:06 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for details</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-04 13:57:08 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Treatment adherence: adherence to chloroquine at day 4 and to primaquine at day 9; measured by participant interview and phenobarbital marker level-to-dose ratios (for each drug separately and for both drugs together)</LI>
<LI>Recrudescence at days 1 to 100</LI>
</OL>
<P>Not included in review:</P>
<OL>
<LI>Reasons for non-adherence</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 15:04:45 +0100" MODIFIED_BY="Jenny Bellorini">
<P>Location: Hunan province, China; conducted in same region as <LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>, but different participants (clarified following correspondence with trialists)</P>
<P>Health facilities: staff highly qualified, each station had good working relationship with provincial authorities</P>
<P>Endemicity: epidemic (imported) malaria</P>
<P>Antimalarial drug resistance: not stated</P>
<P>Malaria diagnosis: microscopically confirmed <I>Plasmodium vivax</I> malaria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-30 08:48:02 +0100" MODIFIED_BY="Anne-Marie Stephani" STUDY_ID="STD-Yeboah_x002d_Antwi-2001">
<CHAR_METHODS MODIFIED="2009-05-30 17:13:47 +0100" MODIFIED_BY="[Empty name]">
<P>Cluster-randomized controlled trial</P>
<P>Generation of allocation sequence: adequate</P>
<P>Allocation concealment: no information provided</P>
<P>Blinding of outcome assessor: none</P>
<P>Completeness of outcome data: number analysed provided but number recruited unclear</P>
<P>Trialists did not take clustering into account in the analysis of this cluster-randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-04 13:57:50 +0000" MODIFIED_BY="[Empty name]">
<P>Participants: facilities randomized rather than participants; 3 intervention facilities (262 participants) and 3 control facilities (247 participants); 190 participants excluded from this review as they did not receive unit-dose packaged drugs; unclear how many were recruited initially</P>
<P>Inclusion criteria: diagnosed with malaria; treated with chloroquine; living in the town of the facility</P>
<P>Exclusion criteria: diagnosed as having malaria but not treated with chloroquine; living outside the town where the facility is located</P>
<P>Mean age: not stated</P>
<P>Age range: adults and children (7+ years)</P>
<P>Male to female ratio: 197:312</P>
<P>Education: 309 none; 170 primary; 30 other</P>
<P>Note: these data are for the entire trial; we have excluded participants receiving syrup from the review<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 18:13:06 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for details</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 08:48:02 +0100" MODIFIED_BY="Anne-Marie Stephani">
<OL>
<LI>Treatment adherence: number completing full treatment in relation to given treatment guidelines. Measured by patient interview and drug inspection</LI>
<LI>Wellness at day 4: participants asked if they were feeling better, same, or worse compared to the day they went to the clinic/hospital</LI>
<LI>Adverse events (reasons for non-adherence/withdrawal)</LI>
</OL>
<P>Not included in review:</P>
<OL>
<LI>Packaging perceptions and acceptance</LI>
<LI>Some costs data</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-08 18:01:32 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Wenchi District, Brong Ahafo Region, Ghana</P>
<P>Health facilities: no data available</P>
<P>Endemicity: intense stable malaria transmission with slight seasonal variations (45.9% to 46.8%)</P>
<P>Antimalarial drug resistance: chloroquine resistance said to be low (only drug used at health centres, health posts and rural clinics)</P>
<P>Malaria diagnosis: confirmed clinically (<I>Plasmodium falciparum </I>is the main cause of morbidity and mortality in this region)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-06-25 14:10:21 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-06-25 14:10:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Agyepong-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-25 14:10:15 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-25 14:10:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Browne-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-25 14:10:17 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-25 14:10:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cullinan-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-25 14:10:18 +0100" MODIFIED_BY="[Empty name]">
<P>Participants included in this trial had severe malaria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Krudsood-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Both treatment groups received identical packaging intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-25 14:10:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okonkwo-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-25 14:10:19 +0100" MODIFIED_BY="[Empty name]">
<P>The packaging used in this trial was not unit-dose packaging</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-25 14:10:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pagnoni-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-25 14:10:20 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shwe-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Both treatment groups received identical packaging interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-25 14:10:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sirima-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-25 14:10:21 +0100" MODIFIED_BY="[Empty name]">
<P>This trial was not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-03-25 17:02:49 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-03-25 17:02:49 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lauwo-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-08 18:12:28 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-05-10 16:13:11 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Blister-packed tablets and capsules versus tablets and capsules in paper envelopes</NAME>
<DICH_OUTCOME CHI2="0.39620014909117784" CI_END="1.2496518107726962" CI_START="1.115688236181674" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1807717072331232" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="244" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.09678902282822213" LOG_CI_START="0.04754285390115054" LOG_EFFECT_SIZE="0.07216593836468632" METHOD="MH" NO="1" P_CHI2="0.5290586108879765" P_Q="0.0" P_Z="9.229634745060381E-9" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="297" WEIGHT="100.0" Z="5.744310397618315">
<NAME>Treatment adherence (measured by interview)</NAME>
<GROUP_LABEL_1>Blister packs</GROUP_LABEL_1>
<GROUP_LABEL_2>Paper envelopes</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours envelopes</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours blister pack</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.250229648524241" CI_START="1.07871083992474" EFFECT_SIZE="1.161308001461454" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="136" LOG_CI_END="0.09698979374915309" LOG_CI_START="0.03290504296355119" LOG_EFFECT_SIZE="0.06494741835635216" ORDER="1" O_E="0.0" SE="0.03764369983609504" STUDY_ID="STD-Li-1998a" TOTAL_1="161" TOTAL_2="163" VAR="0.0014170481373500217" WEIGHT="55.224186173479836"/>
<DICH_DATA CI_END="1.3155157347269428" CI_START="1.103360577252875" EFFECT_SIZE="1.204777241009125" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="108" LOG_CI_END="0.11909604699733406" LOG_CI_START="0.04271746268552406" LOG_EFFECT_SIZE="0.08090675484142905" ORDER="2" O_E="0.0" SE="0.04486515850484712" STUDY_ID="STD-Li-1998b" TOTAL_1="138" TOTAL_2="134" VAR="0.0020128824476650558" WEIGHT="44.775813826520164"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-11-04 14:57:45 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Tablets in sectioned polythene bags versus bottled syrup</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="141" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-04 14:57:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="155" TOTAL_2="144" WEIGHT="0.0" Z="0.0">
<NAME>Treatment adherence (measured by interview)</NAME>
<GROUP_LABEL_1>Sectioned bags</GROUP_LABEL_1>
<GROUP_LABEL_2>Bottles</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours bottles</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bags</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.614692645909445" CI_START="1.7636788128785357" EFFECT_SIZE="2.147435219460603" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="61" LOG_CI_END="0.41742064539046353" LOG_CI_START="0.24641949774867852" LOG_EFFECT_SIZE="0.33192007156957104" ORDER="3" O_E="0.0" SE="0.10044692059411704" STUDY_ID="STD-Ansah-2003" TOTAL_1="155" TOTAL_2="144" VAR="0.010089583856840854" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-05-10 16:13:11 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Tablets in sectioned polythene bags versus polythene bags (unsectioned)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.093035423169655" CI_START="0.9476527948134843" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.017751479289941" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.03863423682420026" LOG_CI_START="-0.02335075223644939" LOG_EFFECT_SIZE="0.007641742293875417" METHOD="MH" MODIFIED="2009-05-10 16:13:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6289086936933608" Q="0.0" RANDOM="NO" SCALE="131.85" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="112" WEIGHT="100.0" Z="0.4832634449762489">
<NAME>Treatment adherence (measured by interview)</NAME>
<GROUP_LABEL_1>Sectioned bags</GROUP_LABEL_1>
<GROUP_LABEL_2>Bags</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sectioned bags</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bags</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.093035423169655" CI_START="0.9476527948134843" EFFECT_SIZE="1.017751479289941" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="104" LOG_CI_END="0.03863423682420026" LOG_CI_START="-0.02335075223644939" LOG_EFFECT_SIZE="0.007641742293875417" MODIFIED="2009-03-25 18:23:22 +0000" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.036410289404869935" STUDY_ID="STD-Lauwo-2006" TOTAL_1="91" TOTAL_2="112" VAR="0.0013257091745463839" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Sectioned polythene bags of chloroquine (from Ghana)</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Blister-packed sulfadoxine-pyrimethamine and amodiaquine (from Rwanda)</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Blister-packed artesunate and mefloquine (from Cambodia)</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-04" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Blister-packed artemether-lumefantrine (trade name Coartem, Novartis)</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-08-04 14:45:28 +0100" MODIFIED_BY="Anne-Marie Stephani">
<APPENDIX ID="APP-01" MODIFIED="2008-11-08 18:08:17 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-08 18:07:31 +0000" MODIFIED_BY="[Empty name]">Search methods: detailed search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-08 18:08:17 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="15">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Search set</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CIDG SR<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CENTRAL</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>MEDLINE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>EMBASE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>LILACS<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>packaging</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>drug packaging</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>drug packaging</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>drug packaging</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>drug packaging</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>tablet</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DRUG PACKAGING</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DRUG PACKAGING</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>capsule</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>tablet</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DRUG DOSAGE FORM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>syrup</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>capsule</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>tablet</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>blister pack</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>syrup</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TABLET</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>unit dose pack</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>blister pack</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>capsule</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>unit dose pack</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>syrup</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6 or 7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>blister pack</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 and 8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>unit dose pack</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MALARIA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 or 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 and 11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MALARIA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 or 12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 and 13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>a</SUP>Cochrane Infectious Diseases Group Specialized Register.<BR/>
<SUP>b</SUP>Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>); upper case MeSH or EMTREE heading; lower case: free text term.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-08-04 14:45:28 +0100" MODIFIED_BY="Anne-Marie Stephani" NO="2">
<TITLE MODIFIED="2008-11-08 18:08:30 +0000" MODIFIED_BY="[Empty name]">Interventions</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-04 14:45:28 +0100" MODIFIED_BY="Anne-Marie Stephani">
<TABLE COLS="6" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Regimen</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Packaging type</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Labels/instructions</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Training/counselling</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Dosage presentation</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3-day regimen of chloroquine</P>
<P>Intervention: tablets</P>
<P>Control: syrup<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: hermetically sealed, sectioned polythene bags with daily dose of tablets in each section</P>
<P>Control: bottles of syrup<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: each section labelled 1, 2, 3 (day to be taken)</P>
<P>Control: unclear<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention and control: prescribers given chart showing appropriate dosage by weight; trained in using chart to tell caregivers how to give the medicine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: 8 dosage presentations available (by weight)</P>
<P>Control: no dosage presentations; all receive 60 ml syrup and instructed to give weight-tailored dose<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>3-day regimen of chloroquine, plus sulphadoxine-pyrimethamine on the first day</P>
<P>Intervention: tablets</P>
<P>Control: tablets</P>
</TD>
<TD VALIGN="TOP">
<P>Intervention: sealed clear sectioned polythene bags stapled to card base with daily dose of tablets in each colour-coded section</P>
<P>Control: separate polythene bags for chloroquine and sulphadoxine-pyrimethamine</P>
</TD>
<TD VALIGN="TOP">
<P>Intervention: name of drugs and instructions written under each section</P>
<P>Control: pen-written instructions</P>
</TD>
<TD>
<P>Intervention and control: counselling given by intern pharmacists from written script covering risks of malaria if treated quickly and appropriately; need to adhere to medication directions, to complete treatment, to seek further medical attention if experience adverse events; and to return to outpatients if no improvement</P>
</TD>
<TD VALIGN="TOP">
<P>Intervention: no dosage presentations available</P>
<P>Control: no dosage presentations available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. 3-day regimen of chloroquine</P>
<P>2. 8-day regimen of primaquine</P>
<P>Intervention and control: tablets<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: 1 boxed blister pack for each drug course; tablets to be taken each day together in 1 blister</P>
<P>Control: paper envelopes<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: drug name on blister pack (back) and box (front); dosage instructions and precautions on back of box; instruction leaflet inside box</P>
<P>Control: none<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: health staff trained to give oral instructions to patients; patients asked to read instruction leaflet and indicate understanding; instructions repeated if poor understanding indicated</P>
<P>Control: health staff trained to give oral instructions to patients; instructions repeated if poor understanding indicated<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: 1 dosage presentation, for adults</P>
<P>Control: none<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. 3-day regimen of chloroquine</P>
<P>2. 8-day regimen of primaquine<BR/>
</P>
<P>Intervention and control: tablets/capsules<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: 1 boxed blister pack for each drug; tablets/capsules to be taken each day together in 1 blister</P>
<P>Control: paper envelopes<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: drug name on blister pack (back) and box (front); dosage instructions and precautions on back of box; instruction leaflet inside box</P>
<P>Control: none<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention and control: no information</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: 1 dosage presentation, for adults</P>
<P>Control: none<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3-day regimen of chloroquine</P>
<P>Intervention and control: tablets<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: hermetically sealed, sectioned polythene bags with daily dose of tablets in each section</P>
<P>Control: paper envelopes<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: bag labelled with name of drug; each section labelled 1, 2, 3 (day to be taken)</P>
<P>Control: none<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: prescribers and dispensers trained in prescribing and dispensing drugs; told to use labelling when instructing participants on how to take medication</P>
<P>Control: same counselling as intervention group in terms of how much drug to take, but there were significant differences in all other aspects of counselling; more participants in the intervention group were told the names of drugs, purpose of drugs, how long to take them, and some possible side effects</P>
<P>Note: staff at the control facilities were more qualified as dispensers than those at the intervention facilities; all participants in the intervention group were served by auxiliary staff with no baseline training; about 2/3 participants in the control group were served by a dispensing assistant/attendant with training in dispensing<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention: 3 dosage presentations available, 1 for each age group: 7 to 11 year; 12 to 15 years; and 16 and above years</P>
<P>Control: no dosage presentations available<BR/>
</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-07-24 15:17:03 +0100" MODIFIED_BY="Jenny Bellorini" NO="3">
<TITLE MODIFIED="2008-11-08 18:09:38 +0000" MODIFIED_BY="[Empty name]">Risk of bias assessment<SUP>a</SUP>
</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-24 15:17:03 +0100" MODIFIED_BY="Jenny Bellorini">
<TABLE COLS="5" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial name</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Allocation sequence generation</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Allocation concealment</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Blinding of outcome assessor</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Inclusion<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ansah-2003" TYPE="STUDY">Ansah 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absent</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lauwo-2006" TYPE="STUDY">Lauwo 2006</LINK>
</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Absent</P>
</TD>
<TD>
<P>Inadequate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Li-1998a" TYPE="STUDY">Li 1998a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absent</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Li-1998b" TYPE="STUDY">Li 1998b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absent</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yeboah_x002d_Antwi-2001" TYPE="STUDY">Yeboah-Antwi 2001</LINK>
<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absent</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>a</SUP>See the '<LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK>' for methods and the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' for the methods used in each trial.<BR/>
<SUP>b</SUP>Inclusion of all randomized participants in the final analysis.<BR/>
<SUP>c</SUP>Trialists did not take clustering into account in the analysis of this cluster-randomized controlled trial.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-11-08 18:10:22 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-11-08 18:09:50 +0000" MODIFIED_BY="[Empty name]">Treatment adherence (level to dose ratio of drug marker; from Li 1998b)</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-08 18:10:22 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="4">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Antimalarial drug</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Tablets and capsules</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Blister packs<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Paper envelopes<SUP>a</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chloroquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of participants: 36</P>
<P>Median: 3.86</P>
<P>Range: 1.2 to 18.85<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of participants: 23</P>
<P>Median: 3.46</P>
<P>Range: 1.99 to 30.9<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primaquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of participants: 31</P>
<P>Median: 7.25</P>
<P>Range: 2.29 to 19.99<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of participants: 34</P>
<P>Median: 7.12</P>
<P>Range: 3.74 to 30.24<BR/>
</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-11-08 18:10:50 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-11-08 18:10:34 +0000" MODIFIED_BY="[Empty name]">Adverse events (from Yeboah-Antwi 2001<SUP>a</SUP>)</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-08 18:10:50 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="4">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Adverse event<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Sectioned bags<SUP>c</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Paper envelopes<SUP>d</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Itching</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12/167</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16/152</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dizziness</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/167</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5/152</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"Other"</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5/167</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/152</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>a</SUP>Cluster-randomized controlled trial.<BR/>
<SUP>b</SUP>Number of participants experiencing the event.<BR/>
<SUP>c</SUP>Sectioned polythene bags (tablets).<BR/>
<SUP>d</SUP>Tablets.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>